WO2012122865A2 - (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 - Google Patents
(e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- WO2012122865A2 WO2012122865A2 PCT/CN2012/071015 CN2012071015W WO2012122865A2 WO 2012122865 A2 WO2012122865 A2 WO 2012122865A2 CN 2012071015 W CN2012071015 W CN 2012071015W WO 2012122865 A2 WO2012122865 A2 WO 2012122865A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- salt
- ethoxy
- cyano
- chloro
- Prior art date
Links
- SADXACCFNXBCFY-IYNHSRRRSA-N CCOc(c(NC(/C=C/[C@@H]1N(C)CCC1)=O)cc1c2Nc(cc3Cl)ccc3OCc3ccccn3)cc1ncc2C#N Chemical compound CCOc(c(NC(/C=C/[C@@H]1N(C)CCC1)=O)cc1c2Nc(cc3Cl)ccc3OCc3ccccn3)cc1ncc2C#N SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N Cc(cc1)ccc1S(O)(=O)=O Chemical compound Cc(cc1)ccc1S(O)(=O)=O JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
Definitions
- the present invention relates to a pharmaceutically acceptable salt of a 6-aminoquinazoline or a 3-cyanoquinoline derivative, a process for the preparation thereof and its use in medicine, in particular (E)-N-[4-[[ 3-Chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-3-[(2R)-l-methyl
- signal transduction transmits various extracellular signals to the interior of cells, allowing cells to respond to biological processes such as proliferation, differentiation, and apoptosis. Most of the signal transduction is achieved by the reversible phosphorylation process of proteins involving specific protein kinases and phosphatases.
- PKs Protein kinases
- PTKs protein tyrosine kinases
- serine-threonine kinases proteins kinases
- STKs PTKs phosphorylate tyrosine residues on proteins
- STKs phosphorylate serine and threonine residues.
- Tyrosine kinases can be further divided into receptor tyrosine kinases (RTKs) and non-receptors.
- RTKs receptor tyrosine kinases
- Non-receptor tyrosine kinase Currently, 90 tyrosine kinase-encoding genes have been identified in human genes, of which about 60 are receptor-type and about 30 are non-receptor-type.
- the RTKs family can be divided into many subfamilies: such as (1) the epidermal growth factor receptor family, members include
- insulin receptor family including insulin receptor IR, insulin-like growth factor I receptor (IGF-IR) and insulin receptor-associated receptor (IRR)
- Type 111 family such as platelet-derived growth factor receptor PDGFR, stem cell factor SCF (c-Kit), fms-related tyrosine kinase 3 (Flt3) receptor and colony stimulating factor 1 receptor (CSF- 1R) and so on.
- hepatocyte growth factor receptor c-Met vascular endothelial growth factor receptor VEGFR, etc. are also members of the RTKs family. They play a key role in regulating cell cycle and differentiation of apoptosis, and are also key signal transduction pathways in signaling pathways that induce cytokine production such as growth factors, see Schlessinger and Ullrich, Neuron 1992, 9, 383.
- the EGFR (ErbB, HER) subfamily plays a very important role in many processes regulating cell proliferation and survival.
- the family receptor consists of three parts: an extracellular ligand binding region, a transmembrane region, and an intracellular catalytic region. Its tyrosine kinase activity is activated by ligand-mediated inter-receptor homotypic or heterodimerization. Dimerization phosphorylates tyrosine residues in the catalytic region of the receptor and acts as a binding molecule for subsequent signals.
- MAP kinase mitogen-activated protein kinase
- PIP-3 kinase phosphatidylinositol kinase
- a compound having an activity of inhibiting tumor cell proliferation can be synthesized, and it is desired to effectively treat and ameliorate mediated by RTKs or STKs and angiogenesis under abnormal conditions by inhibiting one or more of RTKs or STKs.
- the present invention discloses a series of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6
- a pharmaceutically acceptable salt form of -quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide is a more potent protein kinase inhibitor.
- the invention relates to pharmaceutically acceptable salts of the compounds of formula (I), and to methods of preparing the salts.
- the dimaleate salt of the compound of formula (I) has advantages over other salts and the compound of formula (I) in terms of solubility, bioavailability and pharmacokinetics.
- n 1, 2 or 3;
- the first aspect of the invention relates to (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano- represented by formula (I)- a pharmaceutically acceptable salt of 7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide, wherein the salt is Ordinary salts or organic salts conventional in the art.
- the inorganic salt is selected from the group consisting of a hydrochloride, a hydrobromide, a sulfate, a nitrate or a phosphate, preferably a hydrochloride, more preferably a dihydrochloride.
- the organic salt is selected from the group consisting of p-toluenesulfonate, methanesulfonate, maleate, tartrate, succinate, acetate, trifluoroacetate, fumarate, citrate, Citrate, besylate, benzate
- its dimaleate salt has advantages over other salts and the compound of formula (I) in terms of solubility and bioavailability and pharmacokinetics.
- the second aspect of the invention relates to (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6 a process for the preparation of a pharmaceutically acceptable salt of -quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide, which can be prepared according to the practice in the art Prepared by salt formation.
- the method comprises (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy a step of forming a salt of a -6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide with a corresponding acid, wherein the acid is selected from the group consisting of Phosphoric acid, hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, maleic acid, tartaric acid, succinic acid, acetic acid, trifluoroacetic acid, fumaric acid, citric acid, citric acid, benzenesulfonic acid An inorganic or organic acid of benzoic acid, naphthalenesulfonic acid, lactic acid or L-malic acid.
- Typical salts of the invention include, but are not limited to:
- a third aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]- a pharmaceutically acceptable salt of 3-cyano-7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide Medicinal carrier.
- the invention further relates to a process for the preparation of the composition, which process comprises (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3- Medicinal salt of cyano-7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide compound and pharmaceutically acceptable
- the carrier or diluent is combined.
- a fourth aspect of the invention relates to (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-
- a pharmaceutically acceptable salt of 6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide or a pharmaceutical composition thereof for the preparation of a therapeutic protein kinase Use in a medicament for a disease, wherein the protein kinase is selected from the group consisting of an EGFR receptor tyrosine kinase or a HER-2 receptor tyrosine kinase.
- a fifth aspect of the invention relates to a method of treating a protein kinase-related disease, the method comprising administering to a patient in need of treatment a therapeutically effective amount of (E)-N-[4-[[3-chloro-4-(2) -pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]-propyl
- E E-N-[4-[[3-chloro-4-(2) -pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]-propyl
- a sixth aspect of the invention relates to (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-
- a pharmaceutically acceptable salt of 6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide or a pharmaceutical composition thereof for the preparation of a protein kinase inhibitor Use of the protein kinase selected from EGFR or HER-2.
- a seventh aspect of the invention relates to (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano a pharmaceutically acceptable salt of -7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide or a pharmaceutical composition thereof
- An eighth aspect of the invention relates to a method for modulating catalytic activity of a protein kinase, which comprises the protein kinase and (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy) Phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-3-[(2R)-l-methylpyrrolidin-2-yl]prop-2-enamide
- the pharmaceutically acceptable salt is contacted, and the protein kinase is selected from the group consisting of an EGFR receptor tyrosine kinase or a HER-2 receptor tyrosine kinase.
- the structure of the example compounds was determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS).
- NMR shift ( ⁇ ) is given in parts per million (ppm).
- ppm nuclear magnetic resonance
- MS mass spectrometry
- ⁇ is given in parts per million (ppm).
- NMR was measured with Bruker AVANCE-400 NMR instrument, measurement solvent deuterated dimethylsulfoxide W-DMSO), internal standard tetramethylsilane (TMS), chemical shifts are 10- 6 (ppm) as a unit Given.
- the MS was assayed using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
- ESI FINNIGAN LCQAd
- the HPLC was measured using an Agilent 1200 DAD high pressure liquid chromatograph (Sunfire C18 150 x 4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150 x 4.6 mm column).
- the starting materials of the present invention are known and commercially available from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, etc., or may be synthesized or synthesized according to methods known in the art. .
- An argon atmosphere or a nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon having a volume of about 1 L.
- the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon of about 1 L volume.
- the solution means an aqueous solution.
- reaction temperature is room temperature.
- the optimum temperature for the reaction at room temperature is from 20 ° C to 30 ° C.
- the progress of the reaction in the examples was monitored by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the systems used for the reaction were: dichloromethane and methanol systems, n-hexane and ethyl acetate systems, petroleum ether and ethyl acetate systems, The volume ratio of acetone to solvent is adjusted depending on the polarity of the compound.
- the system of the eluent for column chromatography includes: A: dichloromethane, methanol and acetone systems, B: n-hexane and ethyl acetate systems, the volume ratio of the solvent is adjusted according to the polarity of the compound, and may be added less The amount of ammonia water and acetic acid are adjusted.
- A dichloromethane, methanol and acetone systems
- B n-hexane and ethyl acetate systems
- the volume ratio of the solvent is adjusted according to the polarity of the compound, and may be added less
- the amount of ammonia water and acetic acid are adjusted.
- the hydrazine, ⁇ '-carbonyldiimidazole (487 mg, 3 mmol) was dissolved in 4 mL of tetrahydrofuran, the oil bath was heated to 40 ° C, and 4 mL of diethyl phosphate phosphate (588 mg, 3 was added dropwise to the reaction solution. A solution of mmol) in tetrahydrofuran was allowed to react for 30 minutes.
- the activity of the test compound IC 5 can be used. The value is expressed.
- the general protocol for such an experiment is as follows: First, human tumor cells with high expression of EGFR are selected, seeded in 96-well culture plates at a suitable cell concentration (exp 5000 cells/mL medium), and then cultured in a carbon dioxide incubator. When they grow to 85% confluence, the medium is changed to a medium containing a series of concentration (usually 6 to 7 concentrations) of the test compound solution, and the plate is returned to the incubator for 72 hours. After 72 hours, the test compound was tested for its ability to inhibit cell proliferation using the sulforhodamine B (SRB) method. IC 5 . The value can be calculated from the inhibition values of the test compound for the cells at a range of different concentrations.
- the biochemical activity of the compound of the present invention was measured by the above test, and the IC 5 was measured. The values are shown in the table below.
- the methods described below were used to determine the inhibition of EGFR kinase activity by the compounds of the invention.
- the semi-inhibitory concentration of the compound IC 5 (The concentration of the compound measured when the enzyme activity is inhibited to 50%) is determined by mixing a specific substrate with a fixed enzyme and different concentrations of the test compound.
- the EGFR kinase used in this experiment is a human recombinant protein containing 60 mM HEPES (pH 7.5), 5 mM MgCl 2 , 5 mM MnCl 2 , 3 ⁇ Na 3 V0 4 , 1. 1.25 M DTT (lOOOO) and 20 ⁇ .
- the protein kinase activity was quantified using a time-resolved fluorescence method in a buffer solution of ATP in combination with a polypeptide substrate and various concentrations of the test compound (25 C, 45 min). Activity of the compounds of the invention
- the biochemical activity of the compound of the present invention was measured by the above test, and the IC 5 was measured. The values are shown in the table below ;
- the following in vitro cell assay may determine the height of tumor cells expressing HER-2 anti-angiogenic activity of the test compound inhibiting proliferation and its activity is available IC 5.
- the value is expressed.
- the general protocol for such an assay is as follows: First select human tumor cells that highly express HER-2, inoculate them in 96-well culture plates at the appropriate cell concentration, and then culture the cells in a carbon dioxide incubator as they grow to 60%. Confluence, the medium is changed to a medium containing a series of concentration (usually 6 to 7 concentrations) of the test compound solution, and the plate is returned to the incubator for 96 hours. After 96 hours, the test compound can be tested for its ability to inhibit cell proliferation using the sulforhodamine B (SRB) method. IC 5 . The value can be calculated from the inhibition values of the test compound for the cells at a range of different concentrations.
- the biochemical activity of the compound of the present invention was measured by the above test, and the IC 5 was measured. The values are shown in the table below.
- the methods described below were used to determine the inhibition of Her-2 kinase activity by the compounds of the invention.
- the semi-inhibitory concentration of the compound, IC 5 o (the concentration of the compound measured when the enzymatic activity is inhibited to 50%), is determined by mixing a specific substrate with a fixed enzyme and different concentrations of the test compound.
- the Her-2 kinase used in this experiment is a human recombinant protein containing 60 mM HEPES (pH 7.5), 5 mM MgCl 2 , 5 mM MnCl 2 , 3 ⁇ Na 3 V0 4 , 1. 1.25 M DTT (lOOOOx).
- the protein kinase activity was quantified using a time-resolved fluorescence method in a buffer solution of 20 ⁇ M ATP with a polypeptide substrate and various concentrations of the test compound (25 ° C, 45 min). Activity of the compounds of the invention
- the biochemical activity of the compound of the present invention was measured by the above test, and the IC 5 was measured. The values are shown in the table below.
- Rats were used as test animals, and LC/MS/MS method was used to determine the time after intravenous administration of the compound of formula (I) and its different salts and tail vein injection of the compound of formula (I) maleate. The concentration of the drug in the plasma.
- the pharmacokinetic behavior of the compounds of the present invention in rats was evaluated, their pharmacokinetic characteristics were evaluated, and their oral bioavailability was examined.
- Example compound lf example compounds 1, 2, 4, 5, 6, 7 and 9
- Intravenous group weigh the appropriate amount of the drug, add DMSO to dissolve, add physiological saline to the final volume, so that the sample concentration is 2.5 mg / mL;
- Oral administration group Weigh the appropriate amount of the drug, add 0.5% sodium carboxymethylcellulose to grind until the sample is evenly suspended, and the sample concentration is 2.5 mg/mL.
- the compound of the example lf was administered by intragastric administration or tail vein injection, and the example compounds 1, 2, 4, 5, 6, 7 and 9 were administered at a dose of 25 mg/kg (base portion). The dose is 10 m! Jkg.
- Intravenous administration group was placed in heparinized test tubes before and 2 minutes, 15 minutes, 30 minutes, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 hours after administration.
- the plasma was separated by centrifugation at 3500 rpm for 10 minutes and stored at -20 °C.
- the rats in the gavage administration group were subjected to blood collection before administration and 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 hours after administration, and the sample treatment method was the same as the intravenous administration group. Eat 2 hours after administration.
- the maleate salt of the compound of formula (I) has a significant improvement in pharmacokinetic properties and bioavailability compared with the free base and other salts, especially the dimaleate has obvious pharmacokinetic advantages.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013556950A JP6192544B2 (ja) | 2011-03-11 | 2012-02-10 | (e)−n−[4−[[3−クロロ−4−(2−ピリジルメトキシ)フェニル]アミノ]−3−シアノ−7−エトキシ−6−キノリル]−3−[(2r)−1−メチルピロリジン−2−イル]プロプ−2−エナミドの製薬学的に許容される塩、その製造方法及びその医薬用途 |
RU2013143381/04A RU2583056C2 (ru) | 2011-03-11 | 2012-02-10 | Фармацевтически приемлемая соль (е)-n-[4-[[3-хлор-4-(2-пиридилметокси)фенил]амино]-3-циано-7-этокси-6-хинолил]-3-[(2r)-1-метилпирролидин-2-ил]проп-2-енамида, способ ее получения и применение при лечении рака |
ES12757831.8T ES2605564T3 (es) | 2011-03-11 | 2012-02-10 | Sal farmacéuticamente aceptable de (E)-N-[4-[[3-cloro-4-(2-piridilmetoxi)fenil]amino]-3-ciano-7-etoxi-6-quinolil]-3-[(2R)-1-metilpirrolidin-2-il]prop-2-enamida, método de preparación para la misma, y uso médico de la misma |
US14/001,778 US20130338190A1 (en) | 2011-03-11 | 2012-02-10 | Pharmaceutically acceptable salt of (e)-n-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation method thereof, and medical use thereof |
CN201280001564.6A CN102933574B (zh) | 2011-03-11 | 2012-02-10 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
EP12757831.8A EP2684877B1 (en) | 2011-03-11 | 2012-02-10 | Pharmaceutically acceptable salt of (e)-n-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation method therefor, and medical use thereof |
KR1020137025507A KR101871889B1 (ko) | 2011-03-11 | 2012-02-10 | (이)-엔-[4-[[3-클로로-4-(2-피리딜메톡시)페닐]아미노]-3-시아노-7-에톡시-6-퀴놀릴]-3-[(2알)-1-메틸피롤리딘-2-일]프로프-2-엔아미드의 약학적으로 허용 가능한 염, 그의 제조 방법, 및 그의 의학적 용도 |
HK13104640.1A HK1177461A1 (zh) | 2011-03-11 | 2013-04-17 | -氯- -吡啶基甲氧基 苯基 氨基 -氰基- -乙氧基- -喹啉基 -甲基吡咯烷- -基 丙- -烯酰胺的可藥用的鹽、其製備方法及其在醫藥上的應用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100623598A CN102675287A (zh) | 2011-03-11 | 2011-03-11 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
CN201110062359.8 | 2011-03-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012122865A2 true WO2012122865A2 (zh) | 2012-09-20 |
WO2012122865A3 WO2012122865A3 (zh) | 2012-11-08 |
Family
ID=46807903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/071015 WO2012122865A2 (zh) | 2011-03-11 | 2012-02-10 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20130338190A1 (zh) |
EP (1) | EP2684877B1 (zh) |
JP (1) | JP6192544B2 (zh) |
KR (1) | KR101871889B1 (zh) |
CN (2) | CN102675287A (zh) |
ES (1) | ES2605564T3 (zh) |
HK (1) | HK1177461A1 (zh) |
PL (1) | PL2684877T3 (zh) |
PT (1) | PT2684877T (zh) |
RU (1) | RU2583056C2 (zh) |
TW (1) | TWI530288B (zh) |
WO (1) | WO2012122865A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522042A (ja) * | 2012-07-12 | 2015-08-03 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | チロシンキナーゼ阻害剤二マレイン酸塩のi型結晶およびその製造法 |
WO2021037185A1 (zh) * | 2019-08-30 | 2021-03-04 | 江苏恒瑞医药股份有限公司 | 一种低杂质含量的酪氨酸激酶抑制剂 |
CN114409584A (zh) * | 2022-03-08 | 2022-04-29 | 重庆医药高等专科学校 | 一种1-甲基吡咯烷-2-甲醛的制备方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI720115B (zh) | 2016-01-27 | 2021-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種含有喹啉衍生物或其鹽的醫藥組成物的製備方法 |
CA3011525C (en) * | 2016-01-27 | 2023-12-05 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising quinoline derivative or salt thereof |
CN107708698A (zh) * | 2016-01-28 | 2018-02-16 | 江苏恒瑞医药股份有限公司 | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 |
CN108290867B (zh) | 2016-04-28 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 一种制备酪氨酸激酶抑制剂及其衍生物的方法 |
CN107638424B (zh) * | 2016-07-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗癌症的药物中的用途 |
CN108778275A (zh) * | 2017-01-22 | 2018-11-09 | 江苏恒瑞医药股份有限公司 | Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途 |
WO2019076316A1 (zh) | 2017-10-18 | 2019-04-25 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
CA3079916A1 (en) | 2017-10-24 | 2019-05-02 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing quinoline derivative |
EP3700889A4 (en) * | 2017-11-20 | 2020-09-02 | Teligene Ltd. | MALEAT SALTS OF E) -N- (3-CYANO-7-ETHOXY-4 - ((4-PHENOXYPHENYL) AMINO) QUINOLINE-6-YL) -4- (DIMETHYLAMINO) BUT-2-ENAMIDE AND CRYSTALLINE FORMS OF IT |
US10857146B2 (en) | 2018-08-21 | 2020-12-08 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor |
CN110960529A (zh) * | 2018-09-30 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药 |
TWI770934B (zh) * | 2018-10-22 | 2022-07-11 | 大陸商江蘇恒瑞醫藥股份有限公司 | 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法 |
CN111821304A (zh) * | 2019-04-16 | 2020-10-27 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 |
CN112279838B (zh) * | 2020-10-29 | 2021-07-13 | 苏州富士莱医药股份有限公司 | 一种吡咯替尼的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005028443A2 (en) | 2003-09-15 | 2005-03-31 | Wyeth A Corporation Of The State Of Delaware, Usa | Protein tyrosine kinase enzyme inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
KR100486394B1 (ko) * | 1999-11-16 | 2005-04-29 | 쉬바르츠파르마에이지 | 3,3-디페닐-프로필아민의 신규한 유도체의 안정한 염 |
JP2005514384A (ja) * | 2001-11-27 | 2005-05-19 | ワイス・ホールディングズ・コーポレイション | Egf−rおよびher2キナーゼの阻害剤としての3−シアノキノリン |
DE10307165A1 (de) * | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
CN100540552C (zh) | 2007-02-01 | 2009-09-16 | 中国药科大学 | 3-氰基喹啉衍生物、其制备方法及其医药用途 |
US8022216B2 (en) * | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CN101824029A (zh) * | 2009-03-05 | 2010-09-08 | 厦门艾德生物医药科技有限公司 | 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途 |
CN102020639A (zh) * | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用 |
CN107308130B (zh) * | 2009-11-09 | 2021-06-15 | 惠氏有限责任公司 | 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途 |
-
2011
- 2011-03-11 CN CN2011100623598A patent/CN102675287A/zh active Pending
-
2012
- 2012-02-10 PL PL12757831T patent/PL2684877T3/pl unknown
- 2012-02-10 CN CN201280001564.6A patent/CN102933574B/zh active Active
- 2012-02-10 PT PT127578318T patent/PT2684877T/pt unknown
- 2012-02-10 JP JP2013556950A patent/JP6192544B2/ja not_active Expired - Fee Related
- 2012-02-10 KR KR1020137025507A patent/KR101871889B1/ko active IP Right Grant
- 2012-02-10 US US14/001,778 patent/US20130338190A1/en not_active Abandoned
- 2012-02-10 ES ES12757831.8T patent/ES2605564T3/es active Active
- 2012-02-10 EP EP12757831.8A patent/EP2684877B1/en active Active
- 2012-02-10 WO PCT/CN2012/071015 patent/WO2012122865A2/zh active Application Filing
- 2012-02-10 RU RU2013143381/04A patent/RU2583056C2/ru active
- 2012-02-24 TW TW101106172A patent/TWI530288B/zh active
-
2013
- 2013-04-17 HK HK13104640.1A patent/HK1177461A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005028443A2 (en) | 2003-09-15 | 2005-03-31 | Wyeth A Corporation Of The State Of Delaware, Usa | Protein tyrosine kinase enzyme inhibitors |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522042A (ja) * | 2012-07-12 | 2015-08-03 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | チロシンキナーゼ阻害剤二マレイン酸塩のi型結晶およびその製造法 |
EP2873664A4 (en) * | 2012-07-12 | 2015-12-30 | Jiangsu Hengrui Medicine Co | CRYSTALLINE FORM I OF TYROSINE CHINASE INHIBITOR DIMALEATE AND MANUFACTURING METHOD THEREFOR |
AU2013289789B2 (en) * | 2012-07-12 | 2017-06-29 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof |
WO2021037185A1 (zh) * | 2019-08-30 | 2021-03-04 | 江苏恒瑞医药股份有限公司 | 一种低杂质含量的酪氨酸激酶抑制剂 |
CN114409584A (zh) * | 2022-03-08 | 2022-04-29 | 重庆医药高等专科学校 | 一种1-甲基吡咯烷-2-甲醛的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
PT2684877T (pt) | 2017-01-18 |
TW201236684A (en) | 2012-09-16 |
CN102933574A (zh) | 2013-02-13 |
EP2684877A4 (en) | 2014-08-06 |
JP2014507448A (ja) | 2014-03-27 |
JP6192544B2 (ja) | 2017-09-06 |
ES2605564T3 (es) | 2017-03-15 |
HK1177461A1 (zh) | 2013-08-23 |
RU2013143381A (ru) | 2015-04-20 |
CN102933574B (zh) | 2014-10-01 |
KR101871889B1 (ko) | 2018-06-27 |
WO2012122865A3 (zh) | 2012-11-08 |
KR20140009418A (ko) | 2014-01-22 |
EP2684877A2 (en) | 2014-01-15 |
US20130338190A1 (en) | 2013-12-19 |
PL2684877T3 (pl) | 2017-05-31 |
RU2583056C2 (ru) | 2016-05-10 |
EP2684877B1 (en) | 2016-10-19 |
TWI530288B (zh) | 2016-04-21 |
CN102675287A (zh) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012122865A2 (zh) | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 | |
AU2018220045B2 (en) | C-met modulator pharmaceutical compositions | |
JP7383652B2 (ja) | B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
KR20190120766A (ko) | O-아미노헤테로아릴알키닐기를 함유한 화합물 및 이의 제조 방법과 용도 | |
TW201520206A (zh) | 表皮生長因子受體之活化突變形式的喹唑啉抑制劑 | |
WO2012155339A1 (zh) | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 | |
CN107151233B (zh) | 含腙的嘧啶类衍生物及其用途 | |
RU2652992C2 (ru) | Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения | |
NZ752906A (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
JP2020526593A (ja) | N−フェニル−2−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法 | |
WO2011095068A1 (zh) | 吡咯并n杂环类衍生物的可药用的盐、其制备方法及其在医药上的应用 | |
CN108117551B (zh) | 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途 | |
WO2023066296A1 (en) | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof | |
WO2023093859A1 (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
WO2017211248A1 (zh) | 一种取代的咪唑并喹唑啉化合物及其药物组合物 | |
TW202340193A (zh) | 吡唑并嘧啶酮類化合物及其鹽的結晶 | |
TWI482757B (zh) | Vegf-2/3受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途 | |
EP4045484A1 (en) | The salts of a compound and the crystalline forms thereof | |
TW201228664A (en) | Pyrrolo-nitrogenous heterocyclic derivatives pharmaceutical salts, preparation process and pharmaceutical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280001564.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12757831 Country of ref document: EP Kind code of ref document: A2 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012757831 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012757831 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013556950 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14001778 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137025507 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013143381 Country of ref document: RU Kind code of ref document: A |